The Trump administration plans to impose a 100% tariff on imported patented medicines and their active ingredients, with exceptions for certain drugmakers. This move could significantly impact pharmaceutical supply chains and pricing strategies in the U.S., forcing companies to reconsider production locations and pricing models. Meanwhile, Eli Lilly’s obesity pill, Foundayo, received FDA approval, promising a competitive edge over Novo Nordisk's Wegovy due to fewer consumption restrictions, which may drive market growth for oral obesity treatments.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



